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Abstract: Background: Alternative treatment is generally used from the first reporting of HIV/AIDS. Introduction of new 
herbal drugs with antiviral properties may be a significant contribution towards treating HIV-positive patients. This survey 
was thus conducted in order to evaluate preclinical toxicology, clinical safety and efficacy of Faramir.  
Objective: To evaluate preclinical and the clinical safety and efficacy of “Faramir”  
Methods: In the first stage, carried out in 2011, toxicity tests were examined on three groups of six male rats 
administered different dosages of the drug. In the second stage, Phase II clinical trial with Faramir was conducted at the 
Voluntary Counseling and Testing (VCT) Center at Imam Khomeini Hospital, Tehran, Iran from February 2012, as a 
single arm clinical trial. After checking inclusion and exclusion criteria, seven HIV-positive patients received the treatment 
with Faramir tablets containing 330 mg three times a day for six months. The patients were evaluated for the treatment 
efficacy and the possible adverse effects. Patients were also followed for six months after the treatment duration. 
Laboratory tests and CD4 counts were checked each month and viral load was measured each three months. 
Adherence to treatment, clinical observations and adverse effects were registered each month.  
Results: In the toxicity tests, gavages’ administration up to 2 gm/kg showed no poisonous effect or mortality after 72 
hours. Viral load decreased significantly after receiving the treatment duration (P=0.028). The effect of Faramir on viral 
load showed a decrease of virus number in three patients as undetectable. Faramir did not show any serious adverse 
effects except mild skin rashes in three people (42.9%), distension in two people (28.6%), diarrhea in two people 
(28.6%), stomach burn in one person (14.3%), local dry skin in one person (14.3%) and itching in one person (14.3%) 
which were improved without discontinuation of the drug. The symptoms disappeared with necessary treatments. 
Conclusions: In this stage, some evidence was found in support of the efficacy and safety of Faramir. Implementation of 
phase III clinical trial is recommended. 
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INTRODUCTION 
HIV/AIDS is one of the most important infectious 
diseases that affects health worldwide. HIV affects 
human immune system, rendering it too weak to 
defend the body against common infections such as 
tuberculosis. It also increases the risk of other 
opportunistic infections and tumors, through which 
human life is often threatened and lost. Three decades 
after the first description of AIDS, an estimated people 
35 million [33.2 million– 37.2 million] live with HIV in 
2013, with 2.1 million [1.9–2.4 million] new cases 
reported that year. In addition, 1.5 million [1.4–1.7 
million] HIV-infected persons died [1-3].  
There is no definite treatment or effective vaccine 
for HIV infection up to now. Anti-retroviral (ARV)  
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therapy is generally used as the most effective treating 
method for HIV infection. These medications can 
significantly reduce the morbidity and mortality of HIV 
infection although, some HIV strains are resistant to 
antiretroviral drugs. One major limitation for efficacy of 
antiretroviral drugs is multi-drug resistant strains [4-6]. 
Moreover, these drugs are expensive, with 
multiple adverse effects, and they also required strict 
adherence to the medications, especially in developing 
countries. It is reported that ARV medications have 
some serious adverse effects included hepatitis, lactic 
acidosis, cardiovascular side effects and drug reactions 
[7-9]. As a result, the cost and complications of ARV 
drugs encourage considering other treatments and 
medications. For example, it has been found that 
extracts of Croton lechler may reduce the frequency 
and severity of diarrhea in HIV positive patients [10]. 
Similarly calanolide, extracted from Calophyllum 
lanigerun, may bear antiretroviral properties [11]. 
Faramir is composed of a mixture of natural elements 
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with probable antiretroviral properties. We conducted 
this study to evaluate preclinical toxicology in 
laboratory animals and the safety and efficacy of 
Faramir through phase IIA clinical trial among HIV-
positive patients in Tehran.  
MATERIALS AND METHODS 
Study Design 
In the first stage, preclinical toxicology was 
performed in Tehran University of Medical Sciences, 
2011. Toxicity tests were examined on three groups of 
six male rats with mean weight of 160 gms, obtained 
from Karaj Breeding Center. These rats were placed for 
two weeks before the examination in a room with 
controlled temperature and light (a 12-hour light and 
dark cycle), and supplied water ad libitum one day 
before the test. All ethical points on using animals were 
considered and all the experiments were approved by 
the institutional review board. The rats were divided 
into three groups taking different dosages of the drug 
included 0.5, 1 and 2 g/kg. They were subsequently 
followed for 72 hours.  
For the second stage of the study, carried out from 
February 2012 to February 2013, a phase II clinical trial 
was initiated at the Voluntary Counseling and Testing 
(VCT) center in Imam Khomeini Hospital, a referral 
treatment center affiliated with the Tehran University of 
Medical Sciences. There was only one arm and 
Faramir was used in all interventions. HIV infection was 
confirmed by two positive ELISA and one positive 
Western blot test. After taking written consent and 
checking inclusion and exclusion criteria, seven HIV 
positive patients received the treatment with Faramir as 
a 330 mg/tablet administered orally, three times a day 
for six months. The patients were followed for six 
months after the treatment duration and were visited 
regularly to assess their clinical, biochemical, 
immunological, and virological conditions. 
At enrollment time, a medical history and 
comprehensive physical examination were obtained 
and registered in one structured questionnaire and a 
physical assessment form. Patients’ clinical conditions 
were evaluated by carrying out a comprehensive 
physical examination at baseline and each month after 
treatment start. Adherence to treatment and adverse 
effects were registered each month. Effects or possible 
side effects were observed six months after the 
treatment and any adverse events were recorded. 
Pregnancy tests were performed at the baseline and 
whenever pregnancy was suspected. Biochemical 
assays, including Complete Blood Count (CBC), 
platelets, Fasting Blood Sugar (FBS), triglyceride, 
cholesterol, serum electrolytes, amylase, blood urea 
nitrogen (BUN), serum creatinine, uric acid, serum 
bilirubin and liver enzymes, prothrombin time, thyroid 
function test and urinalysis were assessed at baseline, 
followed by the treatment. CD4 counts were 
determined by flow cytometry at the baseline and each 
month, viral loads were measured by a central 
laboratory using quantitative ultrasensitive polymerase 
chain reaction (PCR) at the baseline and each three 
months.  
The PARTEC kit and whole blood was used as a 
sample for CD4 counting. 20 µl of sample was mixed 
with 20 µl of antibody and put it in a dark place for 15 
minutes. Then, 800 µl of buffer was added to the 
mixture before flow cytometry was started.  
For the viral load assay, QIAGEN kit was used to 
extract the RNA from the plasma of HIV positive 
patients. The buffers used in the test were: AVL buffer 
contains RNA carrier and, AW1 and AW2 buffer for 
third and fourth passes and AVE buffer for the last pass 
in centrifuge.  
Patients and Criteria 
The inclusion criteria were as follow: HIV infected 
adults aged between 18-65 years, asymptomatic HIV 
positive patients, patients naïve to any antiretroviral or 
immuno-modulatory therapy, plasma HIV RNA of 
≥1000 copies/mL, CD4+ T cell count ≥200, absolute 
neutrophil count ≥1000/µL, platelets ≥50×103/µL, 
hemoglobin ≥8.0 g/dL, transaminases ≤3 × upper limit 
of normal, serum creatinine <1.5 mg/dL and written 
informed consent.  
Patients were excluded if they had the following 
conditions: pregnancy or breast-feeding for female 
patients, active substance abuse or alcohol 
consumption, hepatitis B surface antigen and hepatitis 
C antibody, receiving therapy for an opportunistic 
infection, taking investigational or immune-modulatory 
drugs and growth hormone within 180 and 30 days 
respectively before entering the study, concurrent 
herpes simplex virus (HSV) infection, patients with 
CD4˂200 cells/mm3, creatinine clearance less than 50 
ml/min tested by Cockroft-Gault equation, using human 
growth hormone 30 days before entering to the study, 
starting testosterone or anabolic steroids 30 days 
before entering to the study, chronic treatment with 
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immuno-suppressant drugs, cytotoxic chemotherapy, 
interferon treatment, or radiation therapy within the 
preceding three weeks and current AIDS defining 
indicator disease including opportunistic infections, 
AIDS dementia, AIDS wasting syndrome and AIDS 
associated malignancy.  
Ethical Considerations 
Seven HIV positive patients recruited in the study 
and were given written informed consent prior to the 
enrollment. Patients were informed totally and made 
aware of the treatment and procedure, then asked to 
sign a consent form. Participation was completely 
voluntary and all patients were notified about the study 
objectives, probable side effects of Faramir and their 
rights as to leaving the project. Patients were notified 
that any probable side effects resulting from the project 
will be covered by the study sponsor. Confidentiality 
was carefully followed during this study and access to 
information was permitted to few authorized 
researchers only. The protocol for this study was 
developed according to the principles of the 
Declaration of Helsinki and was approved by the 
institutional review board (IRB) of Tehran University of 
Medical Sciences (TUMS).  
Statistical Analysis 
Data was analyzed using SPSS software Version 
16. The results were shown as the mean ± SD. Non-
parametric tests of Wilcoxon Signed Rank Test was 
also carried out to examine CD4 count and the viral 
load before and after the intervention. P values of 
<0.05 were considered statistically significant.  
RESULTS 
Preclinical Toxicology 
In the toxicity tests performed on the three groups of 
six male rats, gavages’ administration up to 2 gm/kg 
showed no poisonous effect or mortality after 72 hours. 
Toxicological studies on laboratory animals revealed no 
adverse effects on neither allergic nor immunologic 
effects in the experimental doses.  
Clinical Safety and Efficacy  
Five patients were male and two were female. The 
mean age for the patients was 30.71 years (SD=3.82) 
with the minimum of 24 and maximum of 35 years. 
Table 1 presents the demographic characteristics of 
the patients.  
Table 1: Demographic Characteristics of the Patients 
Attending in the Study 
Variable Categories N (%) 
Gender 
Male 
Female 
5 (71.4) 
2 (28.6) 
Age (years) 
24-29 
30-35 
2 (28.6) 
5 (71.4) 
Marital Status 
Married 
Single 
4 (57.1) 
3 (42.9) 
Occupation 
Employed 
Housewife 
6 (85.7) 
1 (14.3) 
Educational Level 
Junior high school 
Senior high school 
University 
1 (14.3) 
2 (28.6) 
4 (57.1) 
Route of Transmission  
Injection drug use 
Sexual contact 
Unknown 
1 (14.3) 
5 (71.4) 
1 (14.3) 
 
Mean CD4 count and median viral load at the 
baseline was 392.43/µl (SD=132.91) and 3195 
copies/ml, respectively. The patients had near 
complete adherence to Faramir during the treatment 
time.  
The mean CD4 count was increased gradually in 
the third and sixth months; however, compared to the 
baseline level, the increase was not statistically 
significant during six months of the treatment, and the 
CD4 counts showed fluctuation within six months of the 
therapy (Figure 1). Viral load decreased significantly 
after the end of follow up period (P=0.028) compared to 
the baseline. The effect of Faramir on viral load 
showed a decrease in virus number in three patients as 
undetectable (≤20 copies/mL, Figure 2).  
Faramir did not show any serious adverse effects 
except mild skin rashes in three people (42.9%), 
distension in two people (28.6%), diarrhea in two 
people (28.6%), stomach burn in one person (14.3%), 
local dry skin in one person (14.3%) and itching in one 
person (14.3%) which were improved without dis-
continuation of the drug. The symptoms disappeared 
with necessary treatments. Additionally, no sex-based 
differences were identified in the adverse effects of 
Faramir. Most importantly, the clinical examinations of 
various organ systems including cardiovascular, 
gastrointestinal, hepatic, central nervous system 
(CNS), urological, psychiatric, hematological, res-
piratory, ophthalmic, cutaneous and musculoskeletal 
were normal. Furthermore, no laboratory test 
abnormalities were observed in this study.  
Safety and Efficacy of Faramir Journal of Therapy and Management in HIV Infection, 2018, Vol. 6      31 
DISCUSSION 
In this study the preclinical and clinical safety and 
efficacy of Faramir were investigated. There was no 
control group in this stage and the study was initiated 
non-randomized on a small number of HIV positive 
patients. This is due to the fact that it was required to 
confirm the safety of Faramir in the patients before 
examination in the control group. Furthermore, design 
of phase 1 clinical trial on herbal medications is not a 
necessary part of the procedure of making a new 
herbal medication. Many herbal drugs are widely used 
on the market, with possible and recognized side 
effects.  
In the toxicity tests performed on the three groups of 
six male rats, oral administration of Faramir showed no 
poisonous effect or mortality in a short time window.  
The literature review about herbal medicine for 
treatment of HIV+ patients showed that some of herbal 
drugs had positive effects on enhancement of immune 
system, specifically, decreasing viral load or relieving 
symptoms of HIV-positive patients [12-15]. 
Faramir had no effect on CD4 counts during the 
study. It seems that this medication has no direct effect 
on immune system in the short term, and the CD4 
counts showed fluctuation within six months of the 
treatment. Consequently, long-term use of this drug 
may increase CD4 count.  
A study on IMODTM, another natural 
immunomodulator that contains Tanacefi.m vulgare 
(tansy), Rosa canind and Urtica dioica (nettle), 
selenium, flavonoidasn and carotene, found that this 
drug can cause increases in CD4 levels and decrease 
the dissemination of HIV through the host body [12].  
 
Figure 1: CD4 count changes in seven HIV positive patients during 6 months of taking Faramir. 
 
 
Figure 2: HIV viral load changes in seven HIV positive patients during 9 months. 
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The viral load became undetectable in three 
patients. The IMOD study demonstrates that this drug 
had no significant effect on viral load [13].  
A study in Africa assessed effectiveness of herbal 
drugs (without mentioning the name of the drug) on 33 
HIV-positive patients, found significant reduction in viral 
load (85.4%, p = 0.0015) and increase in CD4 count 
(226%, p < 0.0001) after four and eight months and 
recommendations were made as to the use of the drug 
as an alternative or supplementary drug for HIV-
positive patients [14]. 
A recent study in Ghana about the effect of 
combining two herbal drugs, Betula alba (BA) and 
Sutherlandia frutescens (SF) for HIV treatment showed 
increase in white blood cell and lymphocyte counts in 
immunosuppressed mice and decrease in viral load in 
HIV positive patients [15]. 
Another study on a compound of Chinese herbs 
(IGM-1) showed no positive effect, whether on viral 
load and CD4 count or symptoms of HIV positive 
patients after the treatment [16]. 
The effect of Faramir on viral load showed a 
decreased number of HIV in the patients without 
serious side effects. Furthermore, Faramir had minimal 
side effects in the experiment period, suggesting that 
Faramir can be classified as a non-poisonous 
medication. The absence of changes in the laboratory 
profiles revealed that Faramir did not show any 
adverse effects on the blood, liver, kidney or pancreas. 
Some patients presented mild skin rash, distension, 
diarrhea, stomach burn, local dry skin and itching, 
easily was controlled through symptomatic therapy. 
The study on IMOD TM also showed no adverse effect 
in phases ɪ to ɪɪɪ of clinical trials but had some side 
effects in 1-2 % of patients, such as nausea, headache 
and vertigo, gastritis, phlebitis and mild rash [12]. 
Alternative treatment is generally used from the first 
reporting of HIV/AIDS. The cost and complications of 
ARV drugs encourages seeking out other treatments 
and medications. The efficacy of alternative therapies 
has not been discovered unequivocally, although it is 
used common among HIV positive patients [12, 17, 18]. 
A study in China found that combination of a herbal 
drug, namely the Chinese herbal compound SH, and 
antiretroviral (ARV) drugs, increased the effect of ARV 
drugs in comparison with taking ARV drugs alone [19]. 
Antiretroviral treatment decreases the disease 
progression and restores a normal life expectancy. 
Although antiretroviral therapy can reduce the chance 
of death and complications from the infectious 
diseases, these medications are expensive and have 
many adverse effects. The following are the main 
classes of ARV drugs used in treatment of HIV/AIDS 
patients: Nucleoside reverse transcriptase inhibitors 
(NRTIs), Non-nucleoside reverse transcriptase 
inhibitors (NNRTIs) (commonly used in combination 
with NRTIs to inhibit multiplying of the virus), and 
Protease inhibitors (PIs), which suppress the virus 
replication at a later stage in its life cycle, preventing 
cells from producing new viruses. Some common side 
effects of these drugs include fatigue, anemia, 
diarrhea, nausea or vomiting, dizziness or headaches, 
insomnia, pain and nerve problems, skin rash, injection 
site reactions, dry mouth, weight loss and vivid dreams 
[20-22]. Furthermore, given the limitations of ARV 
drugs which can result in mutations in HIV, introduction 
of new herbal drugs such as Faramir with antiviral 
characteristics may be a great help towards treating 
HIV positive people. The results of this study show a 
new effective treatment for HIV positive patients with 
few adverse effects.  
In conclusion, Faramir as a natural drug with 
minimal side effects, and the antiretroviral property can 
be a promising agent to treat patients with HIV/AIDS. In 
the phase II clinical trial, we found some positive 
evidence regarding the therapeutic effect and safety of 
Faramir. Implementation of phase III clinical trial is 
recommended. 
LIST OF ABBREVIATIONS 
HIV = human immunodeficiency virus 
AIDS = acquired immunodeficiency syndrome 
ARV = anti retro-viral 
VCT = voluntary counseling and testing 
ELISA = enzyme-linked immunosorbent assay 
Mg = milligram 
Kg = kilogram 
CBC = Complete blood count 
FBS = Fasting blood sugar 
BUN = blood urea nitrogen 
PCR = polymerase chain reaction 
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RNA = ribonucleic acid 
HSV = Herpes simplex virus 
IRB = institutional review board 
TUMS = Tehran University of Medical Sciences 
SPSS = Statistical Package for the Social Sciences 
SD = standard deviation 
CNS = central nervous system 
NRTI = nucleoside reverse transcriptase inhibitors 
NNRTI = Non-nucleoside reverse transcriptase 
inhibitors 
PI = Protease inhibitors 
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